Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)
Status:
Not yet recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The study is a Phase 2, open-label, randomized, 4-arm, parallel group study in subjects with
active non-infectious uveitis. Subjects will be randomized to receive either 0.1 mg or 1.0 mg
of PL8177 SC injection as 2 single doses 48 hours apart (Group A) or as a single dose for 4
weeks (4 doses) (Group B). A total of 40 subjects are planned to be enrolled with 20
participating in each Group.